Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Accounts Payables (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Accounts Payables for 8 consecutive years, with $12.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accounts Payables rose 121.44% year-over-year to $12.7 million, compared with a TTM value of $12.7 million through Sep 2025, up 121.44%, and an annual FY2024 reading of $15.8 million, up 21.02% over the prior year.
  • Accounts Payables was $12.7 million for Q3 2025 at Bicycle Therapeutics, down from $18.3 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $18.3 million in Q2 2025 and bottomed at $996000.0 in Q1 2021.
  • Average Accounts Payables over 5 years is $7.3 million, with a median of $6.5 million recorded in 2022.
  • The sharpest move saw Accounts Payables crashed 77.54% in 2021, then skyrocketed 301.51% in 2022.
  • Year by year, Accounts Payables stood at $2.7 million in 2021, then skyrocketed by 137.85% to $6.5 million in 2022, then skyrocketed by 101.64% to $13.0 million in 2023, then increased by 21.02% to $15.8 million in 2024, then decreased by 19.88% to $12.7 million in 2025.
  • Business Quant data shows Accounts Payables for BCYC at $12.7 million in Q3 2025, $18.3 million in Q2 2025, and $11.1 million in Q1 2025.